血管免疫母细胞性T细胞淋巴瘤14例临床分析

目的探讨血管免疫母细胞性T细胞淋巴瘤(AITL)的临床病理特征及治疗。方法分析1997年2月至2004年7月收治的14例AITL。结果14例就诊的AITL患者主要症状为全身淋巴结肿大,9例伴有发热等全身症状,3例并发自身免疫性溶血性贫血。病理组织学呈淋巴结结构破坏,免疫母细胞增生,树枝状血管增生的特点,免疫表型全部为T细胞性。14例均用ProMACE-CytaBOM方案化疗,CR3例,PR5例,总有效率57%。2年生存率为60%,全组中位生存25个月,3例缓解的患者已无瘤生存超过5年。结论AITL临床过程呈侵袭性,进展快,中位生存期短,预后差,应探索更为有效的治疗策略。

Angioimmunoblastic T cell lymphoma 14 cases clinical analysis

Objectives To investigate the clinical and pathological characters , treatment of patients with Angioimmunoblastic T cell lymphoma(AITL). Methods From 1997 to 2004, 14 patients with AITL were reviewed retrospectively in our hospital. Results The most common symptoms at the presentation included general lymphadenopathy. 9 patients had fever. 3 patients had autoimmune hemolytic anemia.The histopathologic characteristics of AITL was generalized as:the damage of normal structure of lymphonodus,the proliferation of immunoblastic cell and arborescent supervascularization. All immunophenotyping were T cell type.14 patients were with ProMACE-CytaBOM regimen.The overall response rate was 57% and CR 3 cases, PR 5 cases. Median survival times was 25 months. 2-year survival was 60 %. Conclusions The most cases with AITL runs an aggressive course.The disease may progress rapidly and have unfavorable prognosis. Therefore further studies are repuired to improve the outcome.